In recent years there are many patients who undergo hemodialysis because of chronic renal failure. Along with that, cases where lung cancer is discovered in patients undergoing hemodialysis are increasing. However, a standard chemotherapy for lung cancer patients undergoing maintenance hemodialysis has not yet been established with this in mind, we conducted chemotherapy using carboplatin 300mg/m 2(day 1) plus etoposide 50mg/m 2(day 1, 3) in a patient with limited-stage small cell lung cancer, who was also receiving maintenance hemodialysis. We investigated 16 small-cell lung cancer cases reported since 2000 in Japan that had been treated with carboplatin and etoposide under hemodialysis for chronic renal failure. Reviewing these cases, it is suggested that most effective schedule would be to use a higher dose in the first course followed by dose reduction as necessary for further courses. Although we were able to treat this case safely, the response was limited to an SD(stable disease). Further study is needed to determine the optimal dosage of each drug for small-cell lung cancer with maintenance hemodialysis.
|ジャーナル||Respiration and Circulation|
|出版ステータス||Published - 2009 9月|
ASJC Scopus subject areas